ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2304건의 자료가 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2248 | Completed | A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants | COVID-19 | Biological: BNT162b2 Biological: BNT162b2.B.1.351 |
Phase 3 | BioNTech SE, Pfizer | INDUSTRY | 1574 | All | 12 Years ~ 50 Years | Kaiser Permanente Oakland, Oakland, California, United States Clinical Research Consulting, Milford, Connecticut, United States Indago Research & Health Center, Inc, Hialeah, Florida, United States Research Centers of America, Hollywood, Florida, United States Clinical Neuroscience Solutions, Orlando, Florida, United States Clinical Research Atlanta, Stockbridge, Georgia, United States East-West Medical Research Institute, Honolulu, Hawaii, United States Solaris Clinical Research, Meridian, Idaho, United States Kentucky Pediatric/Adult Research, Bardstown, Kentucky, United States Amici Clinical Research LLC, Raritan, New Jersey, United States Accellacare - Wilmington, Wilmington, North Carolina, United States Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States Texas Center for Drug Development, Inc., Houston, Texas, United States Clinical Trials of Texas, LLC, San Antonio, Texas, United States Martin Diagnostic Clinic, Tomball, Texas, United States J. Lewis Research, Inc. / Foothill Family Clinic South, Salt Lake City, Utah, United States |
| 2247 | Active, not recruiting | A Phase 3b/4 Randomised Trial of 3 Doses of Protein-based Covid-19 Vaccine (SpikoGen) | COVID-19 | Biological: Advax-CpG55.2 adjuvanted recombinant spike protein | Phase 3 | Vaxine Pty Ltd, Australian Respiratory and Sleep Medicine Institute | INDUSTRY | 39 | All | 18 Years | ARASMI, Adelaide, South Australia, Australia |
| 2246 | Not yet recruiting | A Phase Ⅲ Clinical Trial of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) in Booster Vaccination | COVID-19 | Biological: High dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) Biological: Low dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) Biological: control group Biological: Placebo group |
Phase 3 | WestVac Biopharma Co., Ltd. | INDUSTRY | 4950 | All | 18 Years | |
| 2245 | Completed | A Phase I Study to Evaluate Safety, Tolerability, and Immunogenicity of a PIKA COVID-19 Vaccine in Healthy Individuals | COVID-19 Pandemic | Biological: PIKA COVID-19 Vaccine (CHO cell, S-protein), Arm A Biological: PIKA COVID-19 Vaccine (CHO cell, S-protein), Arm B |
Phase 1 | Yisheng Biopharma (Singapore) Pte. Ltd. | INDUSTRY | 135 | All | 18 Years | Al Kuwait Hospital (Al Baraha Hospital), Dubai, United Arab Emirates |
| 2244 | Completed | A Phase I/II Clinical Trial in Healthy People Aged 18 Years and Above | COVID-19 Pandemic | Biological: COVID-19 mRNA vaccine | Phase 2 | Stemirna Therapeutics | INDUSTRY | 480 | All | 18 Years | Mayfong Mayxay, Vientiane, Lao People's Democratic Republic |
| 2243 | Withdrawn | A Phase I/II Study of GLB-COV2-043 as a COVID-19 Vaccine Booster | COVID-19 | Drug: GLB-COV2-043 Drug: BNT162b2/COMIRNATY® |
Phase 2 | GreenLight Biosciences, Inc. | INDUSTRY | 0 | All | 18 Years | |
| 2242 | Unknown status | A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19 | COVID-19 | Biological: NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells | Phase 2 | Chongqing Public Health Medical Center, Chongqing Sidemu Biotech, Zhejiang Qixin Biotech | OTHER | 90 | All | 18 Years | Chongqing Public Health Medical Center, Chongqing, China |
